MDGL
insider transactionsMADRIGAL PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-32.7K
0 buy · 32.7K sell
Net value · 365d
-$16.3M
$0 in · $16.3M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
56
0 buy · 32.7K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
766 sh
Own New
-
Grant·A
Director
$0
454 sh
Own +0%
-
Grant·A
Director
$0
766 sh
Own New
-
Grant·A
Director
$0
454 sh
Own +17%
-
Grant·A
Director
$0
681 sh
Own New
-
Grant·A
Director
$0
404 sh
Own +42%
-
Sell·S
Chief Medical Officer · 10b5-1
$516.6K
1.0K sh · $495.74
Own -9%
-
Sell·S
Chief Medical Officer
$435.4K
844 sh · $515.90
Own -7%
-
Sell·S
President and CEO
$718.3K
1.7K sh · $431.94
Own -1%
-
Sell·S
Director
$212.1K
491 sh · $431.94
Own -0%
-
Sell·S
General Counsel
$155.5K
360 sh · $431.94
Own -3%
-
Sell·S
Chief Commercial Officer
$181.0K
419 sh · $431.94
Own -3%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$17.5K
40 sh · $437.65
Own -0%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$34.9K
80 sh · $436.69
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$34.8K
80 sh · $435.32
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$69.5K
160 sh · $434.20
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$50.2K
116 sh · $432.56
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$51.7K
120 sh · $430.90
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$17.2K
40 sh · $429.58
Own -0%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$68.6K
160 sh · $429.00
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$34.2K
80 sh · $427.85
Own -1%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$179.3K
420 sh · $426.86
Own -3%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$17.0K
40 sh · $425.08
Own -0%
-
Sell·S
Mardi Dier KEY
EVP and CFO · 10b5-1
$279.0K
646 sh · $431.94
Own -4%
-
Grant·A
President and CEO
$0
18.7K sh
Own New
-
Grant·A
President and CEO
$0
15.0K sh
Own +10%
-
Grant·A
Chief Medical Officer
$0
5.5K sh
Own New
-
Grant·A
Chief Medical Officer
$0
4.4K sh
Own +58%
-
Grant·A
General Counsel
$0
5.0K sh
Own New
-
Grant·A
General Counsel
$0
4.0K sh
Own +47%
-
Grant·A
Chief Commercial Officer
$0
5.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
4.0K sh
Own +44%
-
Grant·A
Mardi Dier KEY
EVP and CFO · 10b5-1
$0
6.5K sh
Own New
-
Grant·A
Mardi Dier KEY
EVP and CFO · 10b5-1
$0
5.2K sh
Own +56%
-
Sell·S
Mardi Dier KEY
EVP and CFO
$505.4K
1.2K sh · $427.21
Own -11%
-
Grant·A
Director
$0
57 sh
Own New
-
Grant·A
Director
$0
23 sh
Own +2%
-
Sell·S
President and CEO
$776.5K
1.6K sh · $492.42
Own -1%
-
Sell·S
Director
$318.6K
647 sh · $492.42
Own -0%
-
Sell·S
Chief Commercial Officer · 10b5-1
$281.9K
570 sh · $494.59
Own -6%
-
Sell·S
Chief Commercial Officer · 10b5-1
$167.4K
340 sh · $492.42
Own -3%
-
Sell·S
Director
$1.1M
2.2K sh · $490.77
Own -0%
-
Sell·S
General Counsel · 10b5-1
$215.1K
429 sh · $501.40
Own -5%
-
Sell·S
General Counsel · 10b5-1
$129.1K
263 sh · $490.77
Own -3%
-
Grant·A
Chief Accounting Officer
$0
1.8K sh
Own New
-
Grant·A
Chief Accounting Officer
$0
2.4K sh
Own New
-
Exercise·M
Director · 10b5-1
$0
240 sh
Own New
-
Sell·S
Director · 10b5-1
$110.2K
200 sh · $551.24
Own -0%
-
Sell·S
Director · 10b5-1
$21.8K
40 sh · $545.79
Own -0%
-
Exercise·M
Director · 10b5-1
$3.8K
240 sh · $15.80
Own +0%
-
Exercise·M
Director · 10b5-1
$0
18.4K sh
Own New
-
Sell·S
Director · 10b5-1
$217.1K
400 sh · $542.72
Own -0%
-
Sell·S
Director · 10b5-1
$21.6K
40 sh · $540.26
Own -0%
-
Sell·S
Director · 10b5-1
$215.7K
400 sh · $539.26
Own -0%
-
Sell·S
Director · 10b5-1
$21.5K
40 sh · $537.84
Own -0%
-
Sell·S
Director · 10b5-1
$206.7K
385 sh · $536.88
Own -0%
-
Sell·S
Director · 10b5-1
$160.2K
299 sh · $535.80
Own -0%
-
Sell·S
Director · 10b5-1
$47.6K
89 sh · $534.93
Own -0%
-
Sell·S
Director · 10b5-1
$144.8K
271 sh · $534.18
Own -0%
-
Sell·S
Director · 10b5-1
$21.3K
40 sh · $532.50
Own -0%
-
Sell·S
Director · 10b5-1
$15.9K
30 sh · $531.05
Own -0%
-
Sell·S
Director · 10b5-1
$135.8K
256 sh · $530.45
Own -0%
-
Sell·S
Director · 10b5-1
$293.2K
554 sh · $529.28
Own -0%
-
Sell·S
Director · 10b5-1
$245.6K
465 sh · $528.16
Own -0%
-
Sell·S
Director · 10b5-1
$598.1K
1.1K sh · $526.95
Own -0%
-
Sell·S
Director · 10b5-1
$480.3K
913 sh · $526.05
Own -0%
-
Sell·S
Director · 10b5-1
$781.9K
1.5K sh · $525.12
Own -0%
-
Sell·S
Director · 10b5-1
$699.6K
1.3K sh · $524.06
Own -0%
-
Sell·S
Director · 10b5-1
$382.8K
732 sh · $522.98
Own -0%
-
Sell·S
Director · 10b5-1
$306.9K
588 sh · $521.95
Own -0%
-
Sell·S
Director · 10b5-1
$229.3K
440 sh · $521.11
Own -0%
-
Sell·S
Director · 10b5-1
$280.2K
539 sh · $519.89
Own -0%
-
Sell·S
Director · 10b5-1
$503.1K
970 sh · $518.67
Own -0%
-
Sell·S
Director · 10b5-1
$1.1M
2.0K sh · $517.84
Own -0%
-
Sell·S
Director · 10b5-1
$269.3K
521 sh · $516.81
Own -0%
-
Sell·S
Director · 10b5-1
$814.0K
1.6K sh · $515.82
Own -0%
-
Sell·S
Director · 10b5-1
$482.2K
937 sh · $514.63
Own -0%
-
Sell·S
Director · 10b5-1
$492.6K
960 sh · $513.12
Own -0%
-
Sell·S
Director · 10b5-1
$491.5K
960 sh · $512.02
Own -0%
-
Exercise·M
Director · 10b5-1
$290.9K
18.4K sh · $15.80
Own +4%
-
Grant·A
Director
$0
828 sh
Own New
-
Grant·A
Director
$0
307 sh
Own +30%
-
Grant·A
Director
$0
40.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Rebecca Taub | Grant A | 766 | $0 |
| Jun 17, 2026 | Rebecca Taub | Grant A | 454 | $0 |
| Jun 17, 2026 | James M Daly | Grant A | 766 | $0 |
| Jun 17, 2026 | James M Daly | Grant A | 454 | $0 |
| Jun 17, 2026 | Daniel J. Brennan | Grant A | 681 | $0 |
| Jun 17, 2026 | Daniel J. Brennan | Grant A | 404 | $0 |
| Jun 1, 2026 | David Soergel 10b5-1 | Sell S | 1.0K | $516.6K |
| May 18, 2026 | David Soergel | Sell S | 844 | $435.4K |
| Mar 6, 2026 | William John Sibold KEY | Sell S | 1.7K | $718.3K |
| Mar 6, 2026 | Rebecca Taub | Sell S | 491 | $212.1K |
| Mar 6, 2026 | Shannon T Kelley | Sell S | 360 | $155.5K |
| Mar 6, 2026 | Carole Huntsman | Sell S | 419 | $181.0K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 40 | $17.5K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 80 | $34.9K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 80 | $34.8K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 160 | $69.5K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 116 | $50.2K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 120 | $51.7K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 40 | $17.2K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 160 | $68.6K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 80 | $34.2K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 420 | $179.3K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 40 | $17.0K |
| Mar 6, 2026 | Mardi Dier KEY 10b5-1 | Sell S | 646 | $279.0K |
| Mar 4, 2026 | William John Sibold KEY | Grant A | 18.7K | $0 |
| Mar 4, 2026 | William John Sibold KEY | Grant A | 15.0K | $0 |
| Mar 4, 2026 | David Soergel | Grant A | 5.5K | $0 |
| Mar 4, 2026 | David Soergel | Grant A | 4.4K | $0 |
| Mar 4, 2026 | Shannon T Kelley | Grant A | 5.0K | $0 |
| Mar 4, 2026 | Shannon T Kelley | Grant A | 4.0K | $0 |
| Mar 4, 2026 | Carole Huntsman | Grant A | 5.0K | $0 |
| Mar 4, 2026 | Carole Huntsman | Grant A | 4.0K | $0 |
| Mar 4, 2026 | Mardi Dier KEY 10b5-1 | Grant A | 6.5K | $0 |
| Mar 4, 2026 | Mardi Dier KEY 10b5-1 | Grant A | 5.2K | $0 |
| Mar 2, 2026 | Mardi Dier KEY | Sell S | 1.2K | $505.4K |
| Feb 25, 2026 | Daniel J. Brennan | Grant A | 57 | $0 |
| Feb 25, 2026 | Daniel J. Brennan | Grant A | 23 | $0 |
| Jan 26, 2026 | William John Sibold KEY | Sell S | 1.6K | $776.5K |
| Jan 26, 2026 | Rebecca Taub | Sell S | 647 | $318.6K |
| Jan 26, 2026 | Carole Huntsman 10b5-1 | Sell S | 570 | $281.9K |
| Jan 26, 2026 | Carole Huntsman 10b5-1 | Sell S | 340 | $167.4K |
| Jan 20, 2026 | Rebecca Taub | Sell S | 2.2K | $1.1M |
| Jan 20, 2026 | Shannon T Kelley 10b5-1 | Sell S | 429 | $215.1K |
| Jan 20, 2026 | Shannon T Kelley 10b5-1 | Sell S | 263 | $129.1K |
| Jan 15, 2026 | Rita Thakkar | Grant A | 1.8K | $0 |
| Jan 15, 2026 | Rita Thakkar | Grant A | 2.4K | $0 |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Exercise M | 240 | $0 |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 200 | $110.2K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 40 | $21.8K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Exercise M | 240 | $3.8K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Exercise M | 18.4K | $0 |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 400 | $217.1K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 40 | $21.6K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 400 | $215.7K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 40 | $21.5K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 385 | $206.7K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 299 | $160.2K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 89 | $47.6K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 271 | $144.8K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 40 | $21.3K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 30 | $15.9K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 256 | $135.8K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 554 | $293.2K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 465 | $245.6K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 1.1K | $598.1K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 913 | $480.3K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 1.5K | $781.9K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 1.3K | $699.6K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 732 | $382.8K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 588 | $306.9K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 440 | $229.3K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 539 | $280.2K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 970 | $503.1K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 2.0K | $1.1M |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 521 | $269.3K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 1.6K | $814.0K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 937 | $482.2K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 960 | $492.6K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Sell S | 960 | $491.5K |
| Jan 9, 2026 | Rebecca Taub 10b5-1 | Exercise M | 18.4K | $290.9K |
| Jan 2, 2026 | Daniel J. Brennan | Grant A | 828 | $0 |
| Jan 2, 2026 | Daniel J. Brennan | Grant A | 307 | $0 |
| Jan 2, 2026 | Mardi Dier | Grant A | 40.0K | $0 |
About MDGL insider trading
This page tracks insider transactions for MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.